Trial Profile
A Phase II: Safety and Tolerance of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Adolescent and Young Adults (AYA) With Malignancies Involving the CNS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Mipicoledine (Primary)
- Indications CNS cancer
- Focus Therapeutic Use
- Sponsors Dekk-Tec
- 11 Nov 2021 Status changed from recruiting to completed.
- 28 Apr 2020 Status changed from not yet recruiting to recruiting.
- 28 Apr 2020 Results presented at the 111th Annual Meeting of the American Association for Cancer Research - I